ALIVE is a health-focused venture capital firm based in Israel, known for partnering with major healthcare institutions to back technology companies shaping the future of global health. The firm invests in advanced-stage HealthTech and digital health startups developing solutions that can scale internationally. With strong clinical, operational, and financial backing, ALIVE has established itself as a high-credibility investor capable of leading substantial growth rounds in companies addressing major medical and system-level challenges.
ALIVE targets advanced-stage HealthTech and digital health companies with strong clinical evidence, commercial traction, and clear pathways to global markets. Their investment thesis centers on scalable technologies that improve diagnosis, care delivery, hospital operations, medical devices, and digital therapeutics.
ALIVE announced the initial closing of its ALIVE Growth Fund III in late 2025, marking the beginning of its investment activity. The fund targets approximately $200 million and is designed to invest in advanced-stage growth companies in HealthTech and digital health, both in Israel and internationally.
The strategy builds on the firm’s strong clinical partnerships with leading healthcare groups such as Maccabi, Assuta, and the Carilion Hospital Group in the United States. These partnerships provide ALIVE with privileged access to clinical environments, real-world validation opportunities, and commercial entry points into major healthcare systems.
The fund also benefits from continued support from anchor financial investors including Leumi Partners and Menora, both of which have been long-standing backers of ALIVE since its first fund.
Fund III seeks to lead large financing rounds in breakthrough companies with established traction, scalable business models, and technologies positioned for global expansion. It continues ALIVE’s model of combining strategic hospital partnerships with deep industry knowledge to accelerate late-stage health technology companies.
Leadership
ALIVE is led by its founding partners: Prof. Rafi Beyar, former Director General of Rambam Hospital and a prominent figure in cardiovascular and medical technology development; Prof. Ari Shamiss, former CEO of Assuta Medical Centers; Michel Habib, a seasoned venture investor and growth executive; and Dudi Klein, a veteran of the Israeli health innovation ecosystem with extensive experience in scaling medical and digital health companies. Together, the leadership team integrates clinical expertise, operational depth, and venture capital insight.
Investment Strategy
ALIVE invests in advanced-stage companies, typically at the growth phase, where substantial clinical validation and commercialization potential already exist. Their strategy centers on leading rounds in companies poised for scalable international expansion, particularly those aligned with the needs of large healthcare providers.
The firm leverages its partnerships with major hospitals and health organizations to provide portfolio companies with testing environments, pilot opportunities, feedback loops, and access to global care networks. ALIVE focuses on technologies that can materially improve patient outcomes, reduce operational burdens, strengthen hospital infrastructure, or enable better data-driven medical decision-making.
Notable Investments
Across its first two funds, ALIVE has recorded three exits, including the acquisition of Innovalve by Edwards and the acquisition of Cynerio by Axonius.
Previous portfolio companies span medical devices, hospital infrastructure software, clinical workflow technologies, and digital health platforms with global scaling potential.
Notable Exits
ALIVE has achieved three exits across its Fund I and Fund II portfolios, including the sale of Innovalve to Edwards and the sale of Cynerio to Axonius. Additional exit details have not been publicly disclosed.
Other
Fund III builds on ALIVE’s strong relationships with Israeli and U.S. healthcare systems, giving founders access to commercial validation pathways and strategic hospital environments. The firm is positioned as a leading growth investor in the region’s HealthTech sector, with credibility earned through past performance and deep clinical integration.
For founders, ALIVE offers a rare blend of medical influence, hospital partnerships, and capital leadership that can significantly accelerate market entry and regulatory progress.
Prof. Rafael Beyar - Co-Founder, Managing General Partner
Michel Habib - Co-Founder, Managing General Partner
Israel
